Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Decreases By 73.4%

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) was the target of a large drop in short interest in the month of April. As of April 30th, there was short interest totaling 339 shares, a drop of 73.4% from the April 15th total of 1,276 shares. Based on an average daily volume of 7,336 shares, the days-to-cover ratio is presently 0.0 days.

SAB Biotherapeutics Stock Performance

NASDAQ SABSW traded up $0.00 during mid-day trading on Wednesday, hitting $0.02. The company’s stock had a trading volume of 18,039 shares, compared to its average volume of 22,259. The company’s 50 day simple moving average is $0.03 and its 200 day simple moving average is $0.03. SAB Biotherapeutics has a twelve month low of $0.02 and a twelve month high of $0.18.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biopharmaceutical company specializing in the development of fully human polyclonal antibody therapeutics. The company’s core technology, known as the Transchromosomic (Tc) Bovine platform, leverages genetically engineered cattle to produce large volumes of human antibodies in response to targeted antigens. These antibodies are designed to treat a range of infectious diseases and immunological disorders, offering a complementary approach to monoclonal antibodies and traditional vaccines.

The company’s lead programs focus on combating high-priority pathogens, including emerging coronaviruses and other viral threats.